Dilated cardiomyopathy (DCM) is a disease in which the chambers of the heart enlarge, characterised by left ventricular (LV) dilatation and systolic dysfunction. Many of these patients show an improvement in LV function and clinical outcomes during the course of their disease (1), as has also been observed in other cases of heart failure with reduced ejection fraction (HFrEF) following initial presentation (2-4). Anecdotally, such patients may at times be disinclined to taking medications due to various reasons such as poor compliance, side-effects, hypotension and pregnancy planning. The logical question then arises for those individuals with DCM whose symptoms and LV function have subsequently recovered on pharmacological therapy, is it necessary to continue prognostic medications in the long-term?
Author Sub-editor: Dr May Hu Dr May Hu is a cardiology trainee in the North West deanery. She graduated with First Class Honours from the University
Author Sub-editor: Dr Jhiamluka Solano Dr Jhiamluka Solano is a cardiology resident doctor (ST6) in the Yorkshire and Humber Deanery, currently undertaking a DPhil (PhD)
Author Sub-editor: Dr Justin Chiong Dr Justin Chiong is an NIHR Academic Clinical Fellow and Cardiology Registrar in the North West Deanery. He graduated from
Author Heartbeat Sub-Editor: Marina Zafeiri Dr Marina Zafeiri is an IMT3 in the Wessex deanery, with a strong interest in Cardiology. She graduated from Athens
Author Heartbeat Sub-Editor: Toby MacCarthy Author: Toby MacCarthy
Author Heartbeat Sub-Editor: Toby MacCarthy Author: Toby MacCarthy
